The FTSE 100 soars 5% on vaccine hopes. Is it time to buy these travel stocks?

The recent news of a potential Covid-19 vaccine has seen the FTSE soar. Is this now the perfect time to buy travel stocks?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Last week, I wrote an article about how the FTSE 100 was at its lowest level since March. Since I wrote this article, it has climbed nearly 12%. This has been due to both the ‘Biden bounce’, and news that Pfizer has developed a Covid-19 vaccine with a claimed 90% protection rate. This has caused a number of FTSE 100 stocks to climb rapidly, with a specific focus on travel stocks. But does this positive news make this the perfect time for me to buy these stocks?

This airline stock just soared 38%

After Rolls-Royce, IAG (LSE: IAG) was the largest riser in the FTSE 100 in Monday’s trading. Of course, the travel stock has been heavily affected by the pandemic, and its recent third-quarter trading update saw the company making an operating loss of €3.2bn. The recent imposition of further lockdowns in the UK and Europe has also been disastrous for the travel industry. This follows an incredibly hard summer brought about by the lack of tourism. As such, the British Airways owner has already had to raise £2.5bn in a rights issue to stay afloat. This resulted in share price lows of 66p (down from 260p at the start of the year).

Nevertheless, after the recent news of a potential effective vaccine, there is certainly far more optimism surrounding this stock. For example, it now seems possible a third wave can be avoided, and this could allow the airline owner to return to profitability next year. 

As a result, this particular travel stock now looks to me to be a far more appealing buy than it did a month ago. Although problems do still abound within the travel industry, and there’s uncertainty over when this potential vaccine would be available, I’d now be more tempted to buy IAG shares at some point. Even so, I do still believe that the market has reacted slightly too positively to the vaccine news. On the back of its 40% rise, I’d therefore expect a short-term decline and would wait a little longer before buying.  

This travel stock is a quality operator

National Express (LSE: NEX) is the other travel stock that particularly interests me. While the coach operator has had a dismal 2020, this follows consecutive years of growth, leading to good consumer relationships and strong liquidity. Contracts with local authorities have also allowed the company to offset some of its losses. As such, the recent vaccine news looks capable of propelling National Express shares back towards its former glory, as already shown by a 26% increase yesterday.   

Of course, similarly to IAG, the most recent lockdown will have had a severe effect on the coach operator. I’d therefore continue expecting short-term pain for the FTSE 250 stock. But in the long term, I remain optimistic, especially in the light of vaccine news. As such, I’d buy this stock. Once again, I wouldn’t rush into buying, but would wait, in expectation of the market correcting itself over the next few days.

Stuart Blair owns shares in National Express. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will the S&P 500 crash in 2026?

The S&P 500 delivered impressive gains in 2025, but valuations are now running high. Are US stocks stretched to breaking…

Read more »

Teenage boy is walking back from the shop with his grandparent. He is carrying the shopping bag and they are linking arms.
Investing Articles

How much do you need in a SIPP to generate a brilliant second income of £2,000 a month?

Harvey Jones crunches the numbers to show how investors can generate a high and rising passive income from a portfolio…

Read more »

Investing Articles

Will Lloyds shares rise 76% again in 2026?

What needs to go right for Lloyds shares to post another 76% rise? Our Foolish author dives into what might…

Read more »

Investing Articles

How much passive income will I get from investing £10,000 in an ISA for 10 years?

Harvey Jones shows how he plans to boost the amount of passive income he gets when he retires, from FTSE…

Read more »

Investing Articles

Down 34% in 2025 — but could this be one of the UK’s top growth stocks for 2026?

With clarity over research funding on the horizon, could Judges Scientific be one of the UK’s best growth stocks to…

Read more »

piggy bank, searching with binoculars
Investing Articles

Can the rampant Barclays share price beat Lloyds in 2026?

Harvey Jones says the Barclays share price was neck and neck with Lloyds over the last year, and checks out…

Read more »

Investing Articles

Here’s how Rolls-Royce shares could hit £25 in 2026

If Rolls-Royce shares continue their recent performance, then £25 might be on the cards for 2026. Let's take a look…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

Prediction: in 2026 the red-hot Rolls-Royce share price could turn £10,000 into…

Harvey Jones can't believe how rapidlly the Rolls-Royce share price has climbed. Now he looks at the FTSE 100 growth…

Read more »